<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="933">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04563689</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-POC1</org_study_id>
    <nct_id>NCT04563689</nct_id>
  </id_info>
  <brief_title>Pilot Study to Evaluate Effect of CHX0.12/CPC 0.05 of SARS-CoV-2 Viral Load in COVID-19 Patients</brief_title>
  <official_title>Efecto de un Enjuague Bucal Con Clorhexidina al 0.12% y Cloruro de Cetil Piridinio al 0.05% en la Carga Viral en Saliva en Pacientes COVID-19 + Hospitalizados o Que Esten Recibiendo Cuidado m√©dico en Casa en Cali - 2020.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dentaid SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dentaid SL</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blind, placebo-controlled pilot study to evalaute viral load in saliva of
      COVID19+ patients using quantitative PCR, before and after use of active or placebo rinses
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>exploratory change in viral load</measure>
    <time_frame>baseline (pre-rinse) and 15 min, 1 hour, 2 hours and 5 days after initial oral rinse</time_frame>
    <description>change versus baseline in viral load of SARS-CoV-2 in spontaneous saliva measured by quantitative PCR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of patients who have decrease in viral load of SARS-CoV-2 in spontaneous saliva measured by quantitative PCR</measure>
    <time_frame>15 min, 1 hour, 2 hours and 5 days after initial oral rinse</time_frame>
    <description>number of patients who have decrease in viral load of SARS-CoV-2 in spontaneous saliva measured by quantitative PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with adverse events during 5 days study duration</measure>
    <time_frame>through study completion in day 5</time_frame>
    <description>description of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>actve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral rinse</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>distilled water,</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CHX0.12+CPC0.05 oral rinse (PerioAidActive Control)</intervention_name>
    <description>rinse 15 ml during 1 min during 5 days, twice daily</description>
    <arm_group_label>actve</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo rinse</intervention_name>
    <description>destilled water rinse 15 ml during 1 min during 5 days, twice daily</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be positive for SARS-CoCV-2 real-time PCR test

          2. SARS-CoV-2 patients positive, with home and/or hospitalized care.

          3. Have a medical condition that allows them to perform a mouthwash for 1 minute.

        Exclusion Criteria:

          1. Pregnant.

          2. People with impaired lung function who do not allow them to rinse.

          3. Patients with antiviral treatment for Covid-19.

          4. Patients with diseases that affect saliva, Sjogren's syndrome, and Systemic Lupus
             Erythematosus.

          5. Any cause of immunosuppression (primary or secondary), including HIV.

          6. Chronic kidney disease 3b or older, Coronary heart disease, Uncontrolled diabetes
             (Hb1Ac &gt;7), Uncontrolled high blood pressure, Uncontrolled thyroid disease, history of
             cancer less than 1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruben Leon, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dentaid SL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanessa Blanc, PhD</last_name>
    <phone>34677421423</phone>
    <email>blanc@dentaid.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juan Gispert, MD</last_name>
    <phone>34673886904</phone>
    <email>joan.gispert@dentaid.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Escuela odontologia. Facultad de Salud Hospital del Valle</name>
      <address>
        <city>Cali</city>
        <zip>25360</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adolfo Contreras, prof</last_name>
      <phone>+57 2 316 5243636</phone>
      <email>adolfo.contreras@correounivalle.edu.co</email>
    </contact>
    <contact_backup>
      <last_name>Beatriz Parra, PhD</last_name>
      <phone>+57 2 5542469</phone>
      <email>adolfoco@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2020</study_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

